• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

The EPAD Proof of Concept Platform

The EPAD platform was developed to speed up the development of effective, safe medicines which slow or prevent the development of Alzheimer’s dementia. Although, we were unable to initiate a Proof of Concept Trial, we want to share the EPAD experience on the development of platform trials.

Our trial-ready proof-of-concept (PoC) platform was developed to run Phase II clinical trials with research participants with preclinical and prodromal Alzheimer’s disease, with biomarker evidence of Alzheimer’s disease pathology using a consistent set of outcomes. EPAD was unique in its ability to recruit from the EPAD readiness cohort, guaranteeing recruitment and ensuring a low (10%) screen failure rate.

The platform was open for expressions of interest from pharmaceutical and biotechnology organisations, academic researchers, and funders which had suitable interventions ready for testing.

How Does EPAD Worked?

The platform was designed to efficiently deliver early, accurate results. EPAD studied new drugs in a well-designed Phase II PoC trial with clinical endpoints, utilising the power of adaptive design and Bayesian statistics.

To support this process, we developed three core strategies that offered support and guidance in selecting the optimal trial populations for aspecific compound.

1 The Register

EPAD has created the first single, pan-European register of over half a million people across the risk spectrum for dementia.

2 The Cohort

From this register, participants were invited to join an EPAD cohort, the Longitudinal Cohort Study. This group underwent standardised tests and follow-up over several years.

3 The Trial

EPAD aimed to select suitable participants to take part in streamlined PoC trials of drugs designed to prevent Alzheimer’s dementia.

 

Share this page
FacebookTwitterLinkedInGoogle+
Latest News
  • New paper on the Open-Access EPAD MRI dataset and processing workflow
    2022-07-13
  • Edinburgh Dementia Prevention Summer School 2022
    2022-06-30
  • EPAD at AAIC22!
    2022-06-30
  • ADDI NeuroToolKit Data Hackathon
    2022-05-17
  • The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
    2022-05-09
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

#AAIC2022- that's a wrap! Thank you to all who attended our @IMI_EPAD presentations and stopped by the @AlzData booth! For more information, visit our website: ep-ad.org pic.twitter.com/nvctQFS2F4

reply retweet favorite
9:06 pm · 2022-08-04
Twitter
EPAD
EPAD
@IMI_EPAD

It's the final day of #AAIC2022 and your last chance to visit the @AlzData booth 821. Don't miss out an opportunity to pick up some @IMI_EPAD flyers to learn more about our dataset and samples! #openaccess #datasharing #collaboration ep-ad.org/open-access-da… pic.twitter.com/qkRp70t3jN

reply retweet favorite
2:00 pm · 2022-08-04
Twitter
EPAD
EPAD
@IMI_EPAD

Check out the @AlzData #ADWorkbench to access the final @IMI_EPAD dataset including cognitive, biomarker, genomic and neuroimaging data from over 2000 participants of our Longitudinal Cohort Study. #DataSharing #OpenAccess #AAIC2022 ep-ad.org/open-access-da… pic.twitter.com/t5YwfKEqnf

reply retweet favorite
7:06 pm · 2022-08-03
Twitter
EPAD
EPAD
@IMI_EPAD

We have two @IMI_EPAD posters today at #AAIC2022 - come and join @LuigiLorenzini1 and @cumplido_irene to learn more about their work! @fpmaragall @amsterdamumc pic.twitter.com/elEKbDLlhl

reply retweet favorite
2:00 pm · 2022-08-03
Twitter
EPAD
EPAD
@IMI_EPAD

If you're attending #AAIC2022, stop by @LuigiLorenzini1’s poster today, who is talking about alterations of functional connectivity and WM integrity in relationship to early amyloid deposition. @AlzheimerAms pic.twitter.com/Rve4jEJxtT

reply retweet favorite
6:06 pm · 2022-08-02
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT